A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis

Digestive Diseases and Sciences

Volumn 54, Issue 6, 2009, Pages 1157-1170

  Nikfar, Shekoufeh ^a   Rahimi, Roja ^b   Rezaie, Ali ^c   Abdollahi, Mohammad ^b  

^a MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Balsalazide; Efficacy; Mesalamine; Mesalazine; Meta analysis; Olsalazine; Sulfasalazine; Tolerability

Indexed keywords

BALSALAZIDE; MESALAZINE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ALLERGIC REACTION; ANKLE EDEMA; ANXIETY; ARTHRALGIA; BACKACHE; CENTRAL NERVOUS SYSTEM DISEASE; CERVICAL LYMPH NODE; CHOLESTASIS; CLINICAL TRIAL; COMPARATIVE STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHILIA; ERYTHEMA; ERYTHRODERMA; FATIGUE; FEVER; FLATULENCE; GASTROINTESTINAL DISEASE; HEADACHE; HEARTBURN; HEPATITIS; HUMAN; HYPERSENSITIVITY REACTION; IMPOTENCE; IRRITABILITY; JAUNDICE; KIDNEY COLIC; LASSITUDE; LETHARGY; LIBIDO DISORDER; LIVER FUNCTION TEST; LOOSE FECES; LUNG CARCINOMA; MACROCYTIC ANEMIA; MAINTENANCE THERAPY; MALAISE; META ANALYSIS; METEORISM; MUSCLE FATIGUE; MYALGIA; PARESTHESIA; POLYARTHRITIS; PRIORITY JOURNAL; PRURITUS; RASH; RECURRENCE RISK; REMISSION; REVIEW; RHEUMATIC DISEASE; RISK FACTOR; SIDE EFFECT; SKIN COLOR; SKIN EXFOLIATION; SKIN MANIFESTATION; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; STOMATITIS; SYSTEMATIC REVIEW; THORAX PAIN; TREATMENT DURATION; ULCERATIVE COLITIS; URTICARIA; VOMITING;

AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; HUMANS; SULFASALAZINE;

EID: 67349188746     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-008-0481-x     Document Type: Review

References (52)

1. EH Shen KM Das 2004 Current therapeutic recommendations: infliximab for ulcerative colitis J Clin Gastroenterol 38 741 745 10.1097/01.mcg.0000140188. 88275.65 (Pubitemid 39274172)
2. T Kucharzik C Maaser A Lügering M Kagnoff L Mayer S Targan 2006 Recent understanding of IBD pathogenesis: implications for future therapies Inflamm Bowel Dis 12 1068 1083 10.1097/01.mib.0000235827.21778.d5 (Pubitemid 44665477)
3. A Rezaie S Khalaj M Shabihkhani S Nikfar MJ Zamani A Mohammadirad 2007 Study on the correlations among disease activity index and salivary transforming growth factor-β1 and nitric oxide in ulcerative colitis patients Ann N Y Acad Sci 1095 305 314 10.1196/annals.1397.034 (Pubitemid 47092462)
4. R Rahimi S Nikfar M Abdollahi 2007 Meta analysis technique confirms the effectiveness of anti-TNFa in the management of active ulcerative colitis when administered in combination with corticosteroids Med Sci Monit 13 PI13 PI18 (Pubitemid 47037680)
5. R Rahimi S Nikfar M Abdollahi 2007 Do anti tumor necrosis factors induce response and remission in patients with acute refractory crohn's disease? A meta-analysis of controlled clinical trials Biomed Pharmacother 61 75 80 10.1016/j.biopha.2006.06.022 (Pubitemid 46185874)
6. A Rezaie RD Parker M Abdollahi 2007 Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 52 2015 2021 10.1007/s10620-006-9622-2 (Pubitemid 47246507)
7. G Jahanshahi V Motavasel A Rezaie AA Hashtroudi NE Daryani M Abdollahi 2004 Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases Dig Dis Sci 49 1752 1757 10.1007/s10620-004-9564-5 (Pubitemid 40228532)
8. SB Hanauer 2008 Review article: evolving concepts in treatment and disease modification in ulcerative colitis Aliment Pharmacol Ther 27 S15 S21
9. R Rahimi S Nikfar A Rezaie M Abdollahi 2008 Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis Reprod Toxicol 25 271 275 10.1016/j.reprotox.2007.11.010
10. F Dallegri L Ottonello A Ballestrero F Bogliolo F Ferrando F Patrone 1990 Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis Gut 31 184 186 10.1136/gut.31.2.184 (Pubitemid 20092153)
11. AM Miles MB Grisham 1995 Antioxidant properties of 5-aminosalicylic acid: potential mechanism for its protective effect in ulcerative colitis Adv Exp Med Biol 371B 1317 1321
12. SP Travis DP Jewell 1994 Salicylates for ulcerative colitis-their mode of action Pharmacol Ther 63 135 161 10.1016/0163-7258(94)90042-6 (Pubitemid 24281471)
13. P Desreumaux S Ghosh 2006 Review article: mode of action and delivery of 5-aminosalicylic acid-new evidence Aliment Pharmacol Ther 241 S2 S9 10.1111/j.1365-2036.2006.03069.x (Pubitemid 44267773)
14. B Bat J Lodowska A Orchel B Parfiniewicz L Weglarz Z Dzierzewicz 2004 Evaluation of biotransformation of sulfasalazine in the colon epithelial Caco-2 cells Acta Pol Pharm 61 S8 S10
15. RB Sartor 1997 Review article: role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis Aliment Pharmacol Ther 11 S17 S22 10.1046/j.1365-2036.1997.90262000.x (Pubitemid 28034086)
16. A Swidsinski A Ladhoff A Pernthaler S Swidsinski V Loening-Baucke M Ortner 2002 Mucosal flora in inflammatory bowel disease Gastroenterology 122 44 54 10.1053/gast.2002.30294 (Pubitemid 34049193)
17. P Gionchetti F Rizzello KM Lammers C Morselli L Sollazzi S Davies 2006 Antibiotics and probiotics in treatment of inflammatory bowel disease World J Gastroenterol 12 3306 3313 (Pubitemid 43933773)
18. R Rahimi S Nikfar A Rezaie M Abdollahi 2007 A meta-analysis of antibiotic therapy for active ulcerative colitis Dig Dis Sci 52 2920 2925 10.1007/s10620-007-9760-1 (Pubitemid 47512546)
19. Jadad A. Randomised controlled trials. London: BMJ; 1998.
20. M Egger SG Davey M Schneider C Minder 1997 Bias in meta-analysis detected by a simple, graphical test BMJ 315 629 634 (Pubitemid 27387172)
21. CB Begg M Mazumdar 1994 Operating characteristics of a rank correlation test for publication bias Biometrics 50 1088 1101 10.2307/2533446
22. JC Manfield MH Giaffer PA Cann D McKenna PC Thornton CD Holdsworth 2002 A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis Aliment Pharmacol Ther 16 69 77 10.1046/j.1365-2036.2002.01151.x (Pubitemid 34123866)
23. JR Green JC Manfieldd JA Gibson GD Kerr PC Thornton 2002 A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis Aliment Pharmacol Ther 16 61 68 10.1046/j.1365-2036.2002.01150.x (Pubitemid 34123865)
24. S Ardizzone M Petrillo P Molteni S Desideri G Bianchi Porro 1995 Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study J Clin Gastroenterol 21 287 289 10.1097/00004836-199512000-00007
25. W Kruis G Judmaier L Kayasseh 1995 Double-blind dose-finding study of olsalazine versus sulfasalazine as maintenance therapy for ulcerative colitis Eur J Gastroenterol Hepatol 7 391 396
26. A Nilsson A Danielsson R Löfberg 1995 Olsalazine versus sulfasalazine for relapse prevention in ulcerative colitis: a multicenter study Am J Gastroenterol 90 381 387
27. MC Rijk HJ van Lier JH van Tongeren 1992 Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group Am J Gastroenterol 87 438 442
28. S Kiilerich K Ladefoged T Rannem PJ Ranløv 1992 Prophylactic effects of olsalazine vs. sulfasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group Gut 33 252 255 10.1136/gut.33.2.252
29. R Eliakim D Wengrower M Ligumsky D Rachmilewitz 1990 Comparable efficacy of oral 5-aminosalicylic acid (Mesasal) and sulfasalazine in maintaining ulcerative colitis in remission Isr J Med Sci 26 47 49 (Pubitemid 20079725)
30. P Rutgeerts 1989 Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulfasalazine for maintaining remission of ulcerative colitis. International Study Group Aliment Pharmacol Ther 3 183 191 (Pubitemid 20121780)
31. D Rachmilewitz 1989 Coated mesalamine (5-aminosalicylic acid) versus sulfasalazine in the treatment of active ulcerative colitis: a randomised trial BMJ 298 82 86 (Pubitemid 19032930)
32. SS Rao SA Dundas CD Holdsworth PA Cann KR Palmer CL Corbett 1989 Olsalazine or sulfasalazine in first attacks of ulcerative colitis? A double blind study Gut 30 675 679 10.1136/gut.30.5.675 (Pubitemid 19147082)
33. A Ireland CH Mason DP Jewell 1988 Controlled trial comparing olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis Gut 29 835 837 10.1136/gut.29.6.835 (Pubitemid 18165792)
34. CP Willoughby RE Cowan SR Gould RJ Machell JB Stewart 1988 Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis Scand J Gastroenterol Suppl 148 40 44 10.3109/00365528809101546 (Pubitemid 19003579)
35. PB McIntyre CA Rodrigues JE Lennard-Jones 1988 Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulfasalazine Aliment Pharmacol Ther 2 237 243
36. CJ Mulder GN Tytgat IT Weterman 1988 Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis Gastroenterology 95 1449 1453 (Pubitemid 19016199)
37. SA Riley V Mani MJ Goodman ME Herd S Dutt LA Turnberg 1988 Comparison of delayed release 5 aminosalicylic acid (mesalamine) and sulfasalazine in the treatment of mild to moderate ulcerative colitis relapse Gut 29 669 674 10.1136/gut.29.5.669 (Pubitemid 18145451)
38. SA Riley V Mani MJ Goodman ME Herd S Dutt LA Turnberg 1988 Comparison of delayed-release 5-aminosalicylic acid (mesalamine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis Gastroenterology 94 1383 1389 (Pubitemid 18153638)
39. A Munakata Y Yoshida T Muto 1995 Double-blind comparative study of sulfasalazine and controlled-release mesalamine tablets in the treatment of active ulcerative colitis J Gastroenterol 30l8 S108 S111
40. Andreoli A, Cosintino R, Trotti R, Berri F, Prantera C. 5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission [abstract]. Clin Controversies Inflamm Bowel Dis. 1987;170.
41. XL Jiang HF Cui 2004 Different therapy for different types of ulcerative colitis World J Gastroenterol 10 1513 1520 (Pubitemid 39213905)
42. R Rahimi S Nikfar A Rezaie M Abdollahi 2006 A meta-analysis of broad spectrum antibiotic therapy in patients with active Crohn's disease Clin Ther 28 1983 1988 10.1016/j.clinthera.2006.12.012 (Pubitemid 46215747)
43. SB Hanauer 2006 Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis Aliment Pharmacol Ther 24 37 40 10.1111/j.1365-2036.2006.03058.x (Pubitemid 44326418)
44. RA Ransford MJ Langman 2005 Sulfasalazine and mesalamine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the committee on safety of medicines Gut 51 536 539 10.1136/gut.51.4.536
45. N Mahmud DG Weir D Kelleher 1999 Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease Ir J Med Sci 168 228 232 (Pubitemid 30021192)
46. L Sutherland JK Macdonald 2006 Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis Cochrane Database Syst Rev 19 CD000543
47. L Sutherland JK Macdonald 2006 Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis Cochrane Database Syst Rev 19 CD000544
48. British National Formulary. London: BMJ Publishing Group; 2006;54-55.
49. AM Walker P Szneke LA Bianchi LG Field LR Sutherland NA Dreyer 1997 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis Am J Gastroenterol 92 816 820 (Pubitemid 27200797)
50. Rahimi R, Mozaffari S, Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: A systematic review of animal and human studies. Dig Dis Sci. 2008 Jul 10. [Epub ahead of print].
51. Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci. 2008 Feb 14. [Epub ahead of print].
52. B Elahi S Nikfar S Derakhshani M Vafaie M Abdollahi 2008 On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials Dig Dis Sci 53 1278 1284 10.1007/s10620-007-0006-z